NEW YORK (GenomeWeb News) — OncoMethylome Sciences has tapped Rubicon Genomics to identify and analyze biomarkers that may lead to early cancer detection tests, Rubicon said today.
 
Under the collaboration, Rubicon will use its MethylPlex platform, which identifies multi-gene patterns of abnormal DNA methylation that arise during tumor development, to develop markers that predict the presence of cancer. The agreement also gives OncoMethylome an option to license markers that result from the collaboration.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.